<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002098</url>
  </required_header>
  <id_info>
    <org_study_id>126A</org_study_id>
    <secondary_id>91-10-15</secondary_id>
    <nct_id>NCT00002098</nct_id>
  </id_info>
  <brief_title>Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients</brief_title>
  <official_title>Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AJI Pharma USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To determine the tolerance and side effects of a combination of lentinan and didanosine (ddI)&#xD;
      compared with ddI alone. To determine whether the combination of lentinan and ddI produces a&#xD;
      significant immunorestorative effect within the study observation period (6-12 months) as&#xD;
      measured by an increase in one or more of the following: neutrophil count and activity,&#xD;
      T-cell subsets, and a decrease in p24 antigen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to receive either lentinan (40 patients) or placebo (10 patients) in&#xD;
      combination with ddI for at least 26 weeks; those tolerating their dose may be offered&#xD;
      continuation of therapy for an additional 26 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>50</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lentinan</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Didanosine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV seropositivity.&#xD;
&#xD;
          -  Absolute CD4 count of 200 - 500 cells/mm3.&#xD;
&#xD;
          -  No active opportunistic infection or Kaposi's sarcoma.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Allowed:&#xD;
&#xD;
          -  Prior ddI for no longer than 3 months.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Lymphoid malignancy.&#xD;
&#xD;
          -  Pancreatitis.&#xD;
&#xD;
          -  Peripheral neuropathy.&#xD;
&#xD;
          -  Critical illness.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Antiretroviral agents other than ddI.&#xD;
&#xD;
          -  Steroids.&#xD;
&#xD;
          -  Cytotoxic agents.&#xD;
&#xD;
          -  Immunosuppressive agents.&#xD;
&#xD;
          -  Immunomodulators.&#xD;
&#xD;
          -  1-Thyroxine.&#xD;
&#xD;
        Concurrent Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiotherapy.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded within 1 month prior to study entry:&#xD;
&#xD;
          -  Antiretroviral agents other than ddI (patients may have received prior ddI for no&#xD;
             longer than 3 months total).&#xD;
&#xD;
          -  Steroids.&#xD;
&#xD;
          -  Cytotoxic agents.&#xD;
&#xD;
          -  Immunosuppressive agents.&#xD;
&#xD;
          -  Immunomodulators.&#xD;
&#xD;
        Prior Treatment:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Radiotherapy within 1 month prior to study entry. Active drug abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lang W</last_name>
    <role>Study Chair</role>
  </overall_official>
  <overall_official>
    <last_name>Goodgame J</last_name>
    <role>Study Chair</role>
  </overall_official>
  <location>
    <facility>
      <name>ViRx Inc</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Goodgame Med Group</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gordon M, Guralnik M, Kaneko Y, Mimura T, Goodgame J, DeMarzo C, Pierce D, Baker M, Lang W. A phase II controlled study of a combination of the immune modulator, lentinan, with didanosine (ddI) in HIV patients with CD4 cells of 200-500/mm3. J Med. 1995;26(5-6):193-207.</citation>
    <PMID>8721897</PMID>
  </reference>
  <verification_date>March 1995</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Didanosine</keyword>
  <keyword>Drug Therapy, Combination</keyword>
  <keyword>Acquired Immunodeficiency Syndrome</keyword>
  <keyword>AIDS-Related Complex</keyword>
  <keyword>Lentinan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>HIV Seropositivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Didanosine</mesh_term>
    <mesh_term>Lentinan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

